目的 探討華蟾素膠囊聯(lián)合貝伐珠單抗治療晚期結(jié)直腸癌的臨床療效。方法 選取2015年1月—2017年1月在濮陽市安陽地區(qū)醫(yī)院進行治療的74例晚期結(jié)直腸癌患者，隨機分為對照組（37例）和治療組（37例）。對照組在化療結(jié)束后第2天靜脈滴注貝伐珠單抗注射液，5 mg/（kg·d），持續(xù)時間90 min以上，1次/2周。治療組在對照組的基礎(chǔ)上口服華蟾素膠囊，0.5 g/次，3次/d。兩組患者均經(jīng)過8周治療。觀察兩組患者臨床療效，比較治療前后兩組患者生存質(zhì)量改善情況、細(xì)胞因子水平、腫瘤標(biāo)志物和不良反應(yīng)情況。結(jié)果 治療后，對照組客觀緩解率（ORR）為37.84%，臨床獲益率（CBR）為70.27%，均分別顯著低于治療組的54.05%、89.19%，兩組比較差異均具有統(tǒng)計學(xué)意義（P<0.05）。治療后，對照組生存質(zhì)量改善率為72.97%，明顯低于治療組的91.89%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清低氧誘導(dǎo)因子-1α（HIF-1α）、基質(zhì)金屬蛋白酶-2（MMP-2）、轉(zhuǎn)化生子因子-β1（TGF-β1）、骨橋蛋白（OPN）水平均顯著降低（P<0.05）；且治療組患者細(xì)胞因子水平明顯低于對照組（P<0.05）。治療后，兩組血清癌胚抗原（CEA）、糖蛋白199（CA199）水平均明顯下降（P<0.05）；且治療組比對照組下降更明顯（P<0.05）。治療過程中，治療組不良反應(yīng)發(fā)生率明顯低于對照組患者，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 華蟾素膠囊聯(lián)合貝伐珠單抗治療晚期結(jié)直腸癌可有效改善患者生存質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Huachansu Capsules combined with bevacizumab in treatment of advanced colorectal cancer. Methods Patients (74 cases) with advanced colorectal cancer in Anyang District Hospital in Puyang City from January 2015 to January 2017 were randomly divided into control (37 cases) and treatment (37 cases) groups. Patients in the control group were iv administered with Bevacizumab Injection in 2nd day after chemotherapy, 5 mg/(kg·d), the duration time was more than 90 min, once every 2 weeks. Patients in the treatment group were po administered with Huachansu Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of quality of life, cytokine levels, tumor markers and adverse reaction in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 37.84% and 70.27%, which were significantly lower than 54.05% and 89.19% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement rate of quality of life in the control group was 72.97%, which was significantly lower than 91.89% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, HIF-1α, MMP-2, TGF-β1, and OPN levels in two groups were significantly decreased (P < 0.05). And the cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the CEA and CA199 levels in two groups were significantly decreased (P < 0.05). And these tumor markers levels in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Huachansu Capsules combined with bevacizumab can effectively improve the quality of life in treatment of advanced colorectal cancer, which has a certain clinical application value.